Zacks Investment Research on MSN

AZN, Daiichi's Datroway wins FDA nod for expanded use in breast cancer

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster ...

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative ...

AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer ...
Pharm Exec

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...
Medscape

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...
CURE

FDA Approves Datroway for Triple-Negative Breast Cancer

The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
The American Journal of Managed Care

Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% ...

Gilead Receives Positive Opinions for Breast Cancer Treatment

Gilead Sciences, Inc. (NASDAQ: GILD) shares began the last session before a long week on the right foot. The company announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...